Financials Evolus, Inc.

Equities

EOLS

US30052C1071

Pharmaceuticals

Real-time Estimate Cboe BZX 11:47:08 2024-04-29 am EDT 5-day change 1st Jan Change
11.64 USD +1.84% Intraday chart for Evolus, Inc. -0.60% +10.64%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 406.8 113.4 361.8 422.4 608.2 715.4 - -
Enterprise Value (EV) 1 406.8 113.4 361.8 442.9 608.2 823.4 824.4 715.4
P/E ratio -3.82 x -0.7 x -6.93 x -5.65 x -9.75 x -18.4 x -83.6 x 17.1 x
Yield - - - - - - - -
Capitalization / Revenue 11.6 x 2.01 x 3.63 x 2.84 x 3.01 x 2.72 x 2.08 x 1.6 x
EV / Revenue 11.6 x 2.01 x 3.63 x 2.98 x 3.01 x 3.13 x 2.39 x 1.6 x
EV / EBITDA -4.29 x -2.1 x -8.45 x -10.3 x -26 x -138 x 33.3 x 6.53 x
EV / FCF -4.34 x - - -5.12 x - -21.7 x 38.3 x 6.95 x
FCF Yield -23% - - -19.5% - -4.61% 2.61% 14.4%
Price to Book - - - 22.8 x - -11.4 x -14.3 x -
Nbr of stocks (in thousands) 33,425 33,749 55,577 56,247 57,761 62,594 - -
Reference price 2 12.17 3.360 6.510 7.510 10.53 11.43 11.43 11.43
Announcement Date 2/25/20 3/24/21 3/3/22 3/8/23 3/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 34.92 56.54 99.67 148.6 202.1 263.5 344.3 446.4
EBITDA 1 -94.82 -54.04 -42.8 -43.02 -23.38 -5.97 24.75 109.5
EBIT 1 -98.95 -153.1 -44.4 -65.33 -49.23 -15.84 16.42 72.66
Operating Margin -283.31% -270.73% -44.55% -43.96% -24.36% -6.01% 4.77% 16.28%
Earnings before Tax (EBT) 1 -105.1 -162.9 -46.77 -74.32 -61.51 -30.17 5.317 64.94
Net income 1 -90.03 -163 -46.81 -74.41 -61.68 -36.82 -8.741 41.59
Net margin -257.79% -288.31% -46.96% -50.07% -30.52% -13.98% -2.54% 9.31%
EPS 2 -3.190 -4.830 -0.9400 -1.330 -1.080 -0.6217 -0.1367 0.6700
Free Cash Flow 1 -93.73 - - -86.53 - -38 21.5 102.9
FCF margin -268.37% - - -58.22% - -14.42% 6.24% 23.05%
FCF Conversion (EBITDA) - - - - - - 86.88% 93.94%
FCF Conversion (Net income) - - - - - - - 247.44%
Dividend per Share - - - - - - - -
Announcement Date 2/25/20 3/24/21 3/3/22 3/8/23 3/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 26.68 34.66 33.91 37.16 33.9 43.65 41.72 49.35 50.02 61 57.32 66.07 61.78 76.58
EBITDA 1 -13.4 -11.31 -14.53 -14.1 -13.28 -5.389 -5.896 -8.018 -5.731 -3.74 -0.624 0.388 -7.421 1.687
EBIT 1 -19.12 -18.04 -15.45 -21.35 -17.9 -10.64 -12.04 -15.12 -13.44 -8.635 -7.813 -3.241 -6.773 1.988
Operating Margin -71.68% -52.05% -45.56% -57.44% -52.8% -24.37% -28.86% -30.64% -26.87% -14.16% -13.63% -4.91% -10.96% 2.6%
Earnings before Tax (EBT) 1 -19.43 -18.18 -17.5 -23.44 -20.26 -13.11 -14.77 -18.12 -16.9 -11.72 -11.4 -6.826 -10.36 -1.593
Net income 1 -19.43 -18.18 -17.4 -23.47 -20.28 -13.16 -14.79 -18.14 -16.92 -11.83 -12.55 -8.119 -11.27 -2.795
Net margin -72.85% -52.45% -51.31% -63.16% -59.81% -30.16% -35.45% -36.76% -33.83% -19.4% -21.89% -12.29% -18.24% -3.65%
EPS 2 -0.3500 -0.3300 -0.3100 -0.4200 -0.3600 -0.2300 -0.2600 -0.3200 -0.3000 -0.2000 -0.2175 -0.1375 -0.1925 -0.0475
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/2/21 3/3/22 5/10/22 8/2/22 11/8/22 3/8/23 5/9/23 8/2/23 11/7/23 3/7/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - 20.5 - 108 109 -
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) - - - -0.4765 x - -18.09 x 4.405 x -
Free Cash Flow 1 -93.7 - - -86.5 - -38 21.5 103
ROE (net income / shareholders' equity) - - - -148% - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - - - 0.3300 - -1.000 -0.8000 -
Cash Flow per Share - - - -1.510 - - - -
Capex 1 0.35 0.82 0.39 1.62 - 5 7 5
Capex / Sales 0.99% 1.44% 0.39% 1.09% - 1.9% 2.03% 1.12%
Announcement Date 2/25/20 3/24/21 3/3/22 3/8/23 3/7/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
11.43 USD
Average target price
22.29 USD
Spread / Average Target
+94.98%
Consensus
  1. Stock Market
  2. Equities
  3. EOLS Stock
  4. Financials Evolus, Inc.